Removing race from the CKD-EPI equation and its impact on prognosis in a predominantly White European population.

"CONFLICT OF INTEREST STATEMENT J.J.C. acknowledges consultancy for AstraZeneca, Bayer and Fresenius Kabi, and research funding from AstraZeneca, Amgen and Astellas, all outside the submitted work. C.M.C. has received consultation, advisory board membership or research funding from the Ontario Ministry of Health, Sanofi, Johnson & Johnson, Pfizer, Leo Pharma, Astellas, Janssen, Amgen, Boehringer-Ingelheim and Baxter, all outside the submitted work. J.C. is on the scientific advisory board for Healthy.io. None of the other authors declares relevant financial interests that would represent a conflict of interest. J.C., M.E.G., L.A.I. and A.S.L. have been involved in the development of the 2009 and 2021 CKD-EPI equations."

"FUNDING Research reported in this publication was supported by the Swedish Research Council (#2019–01059), the Swedish Heart and Lung Foundation and the Westman Foundation. E.L.F. acknowledges support by a Rubicon Grant of the Netherlands Organization for Scientific Research (NWO). C.L.R. was supported by a grant from the Dutch Kidney Foundation (20OK016). M.E.G. is supported by NIH grants K24 HL155861, R01 DK115534 and R01 DK100446."